The Impact of Intermediate Antidrug Antibodies to Infliximab and Adalimumab on Clinical Outcomes in Patients with Crohn’s Disease or Ulcerative Colitis

The Impact of Intermediate Antidrug Antibodies to Infliximab and Adalimumab on Clinical Outcomes in Patients with Crohn’s Disease or Ulcerative Colitis

Background: The anti-TNF drugs adalimumab (ADA) and infliximab (IFX) are effective treatments for inflammatory bowel disease (IBD). However, 40% of patients lose response, often due to the development of antibodies-to-ADA (ATA) and antibodies-to-IFX (ATI). While low ATA/ATI titres (<200 ng/mL) a...

Full description

Bibliographic Details
Main Authors: Chaoyang Wang, Mazen Tolaymat, Raymond Cross
Format: Article
Language:English
Published: European Medical Journal 2022-03-01
Series:European Medical Journal
Online Access:https://www.emjreviews.com/gastroenterology/article/the-impact-of-intermediate-antidrug-antibodies-to-infliximab-and-adalimumab-on-clinical-outcomes-in-patients-with-crohns-disease-or-ulcerative-colitis-j190121/

Internet

https://www.emjreviews.com/gastroenterology/article/the-impact-of-intermediate-antidrug-antibodies-to-infliximab-and-adalimumab-on-clinical-outcomes-in-patients-with-crohns-disease-or-ulcerative-colitis-j190121/

Similar Items